Route comparison
IV vs oral vs intranasal ibogaine
Route matters
IV vs oral vs intranasal
Why we work exclusively with intravenous ibogaine and what the evidence does and doesn’t show.
The route we offer
Intravenous (IV)
- Dose titrated in small increments, guided by the ECG and clinical response.
- The infusion can be slowed or stopped at any time.
- Predictable delivery that bypasses first-pass metabolism and gut-absorption variability.
- Given under continuous cardiac (ECG/QTc) monitoring with clinicians present.
Most studied
Oral
- The most studied route in published observational research.
- Once swallowed, the dose can't be reversed or titrated down.
- Absorption varies with the gut and with CYP2D6 metabolism.
Not offered
Intranasal
- Very little clinical data.
- Unpredictable absorption.
- Not a route we offer.
IV ibogaine is still being researched, and every route carries serious cardiac risk, so screening is essential. Nothing here is a promise of cure or benefit.
Reading the evidence honestly
Most published ibogaine research is observational and uses oral dosing. Controlled data on psychoactive IV ibogaine remain limited. The advantage of IV is control: clinicians can adjust or stop delivery while watching the ECG. That does not remove cardiac risk, which is why screening decides who can be treated.
Learn more on safety and screening and what true IV infusion means.
Request early access
Join the waitlist
Intake opens in small, physician-screened cohorts. Places are limited because every infusion has one-to-one cardiac monitoring. Waitlist members get first access to screening and the intake date.
Now accepting waitlist intakes for two locations: Mexico and Gabon.